3DBio is a technology company.
3DBio is a technology company.
3DBio has raised $1.0M across 1 funding round.
3DBio has raised $1.0M in total across 1 funding round.
3DBio has raised $1.0M in total across 1 funding round.
3DBio's investors include Freestyle Capital.
3DBio Therapeutics is a clinical-stage regenerative medicine company that develops 3D-bioprinted living tissues for therapeutic applications, focusing on replacing or repairing damaged or diseased tissues with patient-specific implants. Their proprietary technology platform, GMPrint™, enables the creation of functional, living tissue implants tailored to individual patients. Their lead product, AuriNovo™, targets microtia (a congenital ear deformity) by producing 3D-bioprinted, patient-specific ear implants. The company serves patients with unmet medical needs in regenerative medicine and aims to translate scientific breakthroughs into clinical solutions. 3DBio operates primarily in the United States but has global implications through potential collaborations and future expansions[1][2][4].
Founded in 2014 and headquartered in Long Island City, New York, 3DBio Therapeutics was established by innovators with a background in regenerative medicine and bioprinting technologies. The idea emerged from the need to create personalized, living tissue implants that could overcome limitations of traditional reconstructive surgeries. Early pivotal moments include the development of their four-part technology platform—comprising the GMPrint 3D-bioprinter, ColVivo bio-ink, specialized cell culture, and implantable protective shells—and the successful clinical implantation of their first product, AuriNovo, which uses a biopsy from the patient’s own ear remnant to bioprint a new ear[4][7].
3DBio Therapeutics rides the growing trend of regenerative medicine and personalized bioprinting, which aims to revolutionize tissue repair and organ replacement. The timing is critical as advances in 3D bioprinting, biomaterials, and cell biology converge with increasing demand for patient-specific therapies. Market forces favor companies that can offer scalable, customizable, and FDA-compliant bioprinted tissues, especially for congenital defects and injuries. By pioneering clinical applications of bioprinted living tissues, 3DBio influences the broader ecosystem by setting technological and regulatory precedents, fostering collaborations, and expanding the potential of regenerative medicine globally[1][3].
Looking ahead, 3DBio Therapeutics is poised to expand its clinical pipeline beyond microtia to other tissue types and therapeutic areas, leveraging its platform’s versatility. Trends such as advances in bio-inks, automation in bioprinting, and regulatory frameworks for regenerative therapies will shape their journey. Their influence is likely to grow as they demonstrate clinical efficacy and scale manufacturing capabilities, potentially transforming reconstructive surgery and regenerative treatments. Continued innovation and strategic partnerships will be key to maintaining leadership in this emerging field and fulfilling their mission to provide personalized, living tissue implants to patients worldwide[1][4][7].
3DBio has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in February 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2022 | $1.0M Seed | Freestyle Capital |